The Latin phrase Omne Trium Perfectum translates to a simple but profound concept: everything that comes in threes is perfect.
As a principle, the “Rule of Three” dictates that information is most easily digested, retained, and recalled when delivered in a triad. From storytelling to safety protocols, our brains are hardwired to look for this pattern. In storytelling, it provides a beginning, a middle, and an end. In literature, it has produced timeless stories of the Three Musketeers, the Three Little Pigs, and Goldilocks and the Three Bears. It even shapes our approach to medicine through “See one. Do one. Teach one.”, “history, examination, investigation”, and “airway, breathing, circulation”.1,2
This pattern also translates seamlessly into public health. Consider the NHS “Catch it. Bin it. Kill it.” campaign: its clear, three-part rhythm provided memorable guidance that empowered the public to help reduce the spread of respiratory infections, from seasonal flu to COVID-19.3,4
The challenges of protecting older adults from flu
Protecting older adults against seasonal flu presents clinical challenges that require thoughtful, targeted solutions.
First, natural aging brings immunosenescence. Starting around age 50, our immune system gradually weakens, making it harder for older adults and those with underlying health conditions to construct a durable, lasting response to standard flu vaccines.5
Second, many older individuals experience inflammaging. A state of low-grade, chronic inflammation often linked to aging and long-term health conditions. This persistent immune dysregulation leaves vulnerable patients at a significantly higher risk of severe flu complications.5
Finally, traditional egg-based manufacturing can lead to egg adaptation. Because some flu strains struggle to grow in hens’ eggs, they can mutate during production. These subtle structural changes mean the resulting vaccine may produce antibodies that are less effective against circulating wild-type strains.5,6
Three Trusted Approaches, One Enhanced Vaccine
Aujemflu ▼ (Influenza vaccine, surface antigen, inactivated, adjuvanted, prepared in cell culture) is the only enhanced seasonal influenza vaccine which combines the benefits of three trusted vaccine approaches designed to help address the specific challenges of protecting adults aged ≥50 years.5,7
Cell-based
Aujemflu is manufactured using mammalian cell lines, designed to be an exact match to the WHO recommended flu strains and eliminating egg-based adaptations.5,7
Adjuvant
Aujemflu contains 2X the dose of adjuvant MF59® compared to aTIV, which is designed to increase and broaden the antigen-specific immune response and to extend the duration of the immune response.5,7
Higher dose
Aujemflu contains three times the dose of antigens (45 μg antigen per strain) compared to standard-dose vaccines. Higher antigen doses are shown to increase the magnitude of the immune response.5,7
Take on the 2027/28 flu season with confidence
Whether it is a timeless story, a public health campaign, or the approach to flu immunisation, three truly is the magic number. By combining cell-based manufacturing, MF59® adjuvant, and a higher antigen dose, Aujemflu represents a paradigm shift in how we vaccinate vulnerable adults aged ≥50.5,7
Visit Flu360.co.uk, email flu.salesuk@seqirus.com, or call 0345 009 3804 today to secure your influenza vaccine orders for the 2027/28 season.
Pre-book now and take on the next flu season with confidence.
Aujemflu ▼ Prescribing and Adverse Event Reporting Information
References
- Aronson JK. When I use a word… Medical powers of three. BMJ. 2025;391:r2357.
- Brito AMP & Schreiber M. x-ABC versus ABC: shifting paradigms in early trauma resuscitation. Trauma Surg Acute Care Open. 2025;10(Suppl 1):e001773.
- Department of Health and Social Care. ‘Catch it. Bin it. Kill it.’ campaign to help reduce flu infections. January 2013. Available from: https://www.gov.uk/government/news/catch-it-bin-it-kill-it-campaign-to-help-reduce-flu-infections (Accessed October 2026).
- NHS Infection Prevention Control. Catch it, Bin it, Kill it Poster. March 2020. Available from: https://www.infectionpreventioncontrol.co.uk/resources/catch-it-bin-it-kill-it-poster/. (Accessed October 2026)
- Ashraf M, et al. Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness. Expert Rev Vaccines. 2026:2667732.
- Ashraf M, et al. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness. Vaccine. 2025:62:127393.
- Seqirus UK Ltd. Aujemflu Summary of Product Characteristics. June 2026. Available from: https://www.medicines.org.uk/emc/product/102343/smpc (Accessed October 2026).
This article was written and funded by CSL Seqirus.
GBR-aTIVc-26-0088 | October 2026